Literature DB >> 24368533

Differentiated thyroid carcinoma: an analysis of 249 patients undergoing therapy and aftercare at a single institution.

Amr Amin1, Ahmed Badwey, Sherif El-Fatah.   

Abstract

PURPOSE: Well-differentiated thyroid cancer (WDTC) is rising in incidence across the world over the past 3 decades. We aimed to evaluate the natural history and clinical outcome of differentiated thyroid carcinoma by a retrospective analysis of 249 patients treated at a single institution.
METHODS: A cohort of 249 patients who underwent thyroidectomy for WDTC in the last 10 years in Maadi Military Hospital was studied. Main outcome measures were clinical management at the diagnosis, survival, morbidity, and prognostic risk factors.
RESULTS: Mean age at diagnosis was 44.7 (SD, 14.6) years, where 52.2% were 45 years or older. Females represent 70.7% (P = 0.01), with female-to-male ratio of 4.1:1. Near-total thyroidectomy was done in 70.7% of the cases where papillary cancer was found in 80.8% and node metastasis in 10.5%. Radioactive I (RA I) was given an all cases (dose range, 80-150 mCi) with ablation success rate of 79.2%. Locoregional recurrence and metastasis (lungs and bones) were found in 2% and 6.8%, respectively. Multivariate Cox regression analysis showed that the mean ablation dose of RA I (odds ratio, 1.045; 95% confidence interval, 0.936-1.1189; P = 0.01) and presence of remote deposits (odds ratio, 1.049; 95% confidence interval, 0.836-1.1189; P = 0.01) are the significant influential factor in ablation success rate and survival, respectively.
CONCLUSIONS: Our data suggest that proper ablation dose of RA I and absence of remote metastasis are the powerful predictors for excellent outcome in WDTC patients.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24368533     DOI: 10.1097/RLU.0000000000000324

Source DB:  PubMed          Journal:  Clin Nucl Med        ISSN: 0363-9762            Impact factor:   7.794


  6 in total

Review 1.  Treatment strategies for radioactive iodine-refractory differentiated thyroid cancer.

Authors:  Francis Worden
Journal:  Ther Adv Med Oncol       Date:  2014-11       Impact factor: 8.168

2.  Risk Haplotypes Uniquely Associated with Radioiodine-Refractory Thyroid Cancer Patients of High African Ancestry.

Authors:  Zachary Hurst; Sandya Liyanarachchi; Huiling He; Pamela Brock; Jennifer Sipos; Fadi Nabhan; Electron Kebebew; Patience Green; Gilbert J Cote; Steven Sherman; Christopher J Walker; Yi Seok Chang; Shuai Xue; Brynn Hollingsworth; Wei Li; Luke Genutis; Eric Menq; Albert de la Chapelle; Sissy M Jhiang
Journal:  Thyroid       Date:  2019-02-13       Impact factor: 6.568

Review 3.  EMT, CTCs and CSCs in tumor relapse and drug-resistance.

Authors:  Abhisek Mitra; Lopa Mishra; Shulin Li
Journal:  Oncotarget       Date:  2015-05-10

4.  Well-Differentiated Thyroid Cancer: The Philippine General Hospital Experience.

Authors:  Tom Edward N Lo; Abigail T Uy; Patricia Deanna D Maningat
Journal:  Endocrinol Metab (Seoul)       Date:  2016-03

5.  Development of an athyroid mouse model using 131I ablation after preparation with a low-iodine diet.

Authors:  Ji Min Oh; Ho Won Lee; Senthilkumar Kalimuthu; Prakash Gangadaran; Se Hwan Baek; Man-Hoon Han; Chae Moon Hong; Shin Young Jeong; Sang-Woo Lee; Jaetae Lee; Byeong-Cheol Ahn
Journal:  Sci Rep       Date:  2017-10-16       Impact factor: 4.379

6.  Predictors of Response to Therapy Among Post Thyroidectomy Adult Filipino Patients with Papillary Thyroid Carcinoma Based on the 2015 American Thyroid Association Guidelines.

Authors:  Aivind Gabrielle Santiago; Maria Jocelyn Isidro; Joseph Parra
Journal:  J ASEAN Fed Endocr Soc       Date:  2021-10-05
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.